Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism

Wen Yi et al.

*Science* 337, 975 (2012);

DOI: 10.1126/science.1222278

This copy is for your personal, non-commercial use only.
displayed a subunit composition comparable to that of the wild-type complex (fig. S12B). Moreover, ectopic expression of wild-type mouse Su(z)12 efficiently rescued the deficiency of H3K27me3 levels in Su(z)12 null embryonic stem (ES) cells (21), but ectopic expression of comparable amounts of mouse Su(z)12 mutated at the same residues showed a much poorer rescue effect (Fig. 3E). These results collectively suggest that allosteric activation of PRC2 by neighboring nucleosomes is important for the establishment of H3K27me3 in vivo.

We propose that active genes are resistant to PRC2 activity not only because they carry active marks (such as H3K4me3, H3K36me2, and H3K36me3) that antagonize PRC2 activity (20, 22) but also because the chromatin of actively transcribing genes is less compact, with a lower nucleosome density and a lower linker histone H1 content (5). Once active transcription has ceased upon transcription factor dissociation, either the chromatin-remodeling events or the incorporation of additional histones (including linker histones) would lead to higher nucleosome density, higher H1 content, and more compact chromatin structure, which in turn would convert these nucleosomes from their inert status to ideal substrates of PRC2. Thus, H3K27me3 could be established and lead to further repression of the target genes (fig. S13).

We studied the kinetics of chromatin compaction and H3K27me3 establishment in an ~1.8-kb region around the transcription start site of the CYP26a1 gene (Fig. 4A) upon transcription cessation, because CYP26a1 is an inducible gene regulated by retinoic acid (23) and a well-established Polycomb target repressed by H3K27me3 (23, 24). Mouse ES cells were treated with retinoic acid for 36 hours to induce CYP26a1 expression. Retinoic acid was then withdrawn to end the induction, and the cells were harvested at various time points after retinoic acid withdrawal (Fig. 4, B and C) to monitor the dynamic changes of the chromatin compaction status and H3K27me3 levels. The chromatin compaction status was determined by a nuclease accessibility assay (25). The tested regions displayed much more “open” structures upon induction, and they began to be less accessible at 2 to 4 hours and fully compacted at 8 hours after retinoic acid withdrawal (Fig. 4D). The establishment of H3K27me3 began at 8 hours and was complete at 36 hours after retinoic acid withdrawal (Fig. 4E). These results suggest that the local chromatin compaction precedes the establishment of H3K27me3, in agreement with our model.

The ability of PRC2 to distinguish active chromatin (open, marked by H3K4me3 and H3K36me3) from inactive chromatin (dense, marked by H3K27me3) provides a mechanistic explanation of how PRC2-dependent H3K27me3 is important for the establishment of H3K27me3 in vivo. Furthermore, the dynamic posttranslational modification of proteins with O-linked N-acetylglucosamine (O-GlcNAcylation) is a key metabolic regulator of glucose metabolism. O-GlcNAcylation was induced at serine 529 of phosphofructokinase 1 (PFK1) in response to hypoxia. Glycosylation inhibited PFK1 activity and redirected glucose flux through the pentose phosphate pathway, thereby conferring a selective growth advantage on cancer cells. Blocking glycosylation of PFK1 at serine 529 reduced cancer cell proliferation in vitro and impaired tumor formation in vivo. These studies reveal a previously uncharacterized mechanism for the regulation of metabolic pathways in cancer and a possible target for therapeutic intervention.

References and Notes

2. B. Czermim et al., Cell 111, 185 (2002).

Supplementary Materials

www.sciencemag.org/cgi/content/full/337/6097/971/DC1 Materials and Methods
Supplementary Text
Figs. S1 to S16

Acknowledgments: We appreciate K. Helin and Y. Shinkai for providing the Su(z)12 null and T22 ES cells. This work was supported by the Chinese Ministry of Science and Technology (grants 2011CB101200 and 2011CB101200 to B.Z.), the Howard Hughes Medical Institute International Early Career Scientist Program to B.Z., and NSF Career award 0747475 (to X.J.Z.).

References and Notes

Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism

Wen Yi,1,2 Peter M. Clark,1,2 Daniel E. Mason,3 Marie C. Keenan,4 Collin Hill,4 William A. Goddard III,5 Eric C. Peters,3 Edward M. Driggers,4 Linda C. Hsieh-Wilson1,2

Cancer cells must satisfy the metabolic demands of rapid cell growth within a continually changing microenvironment. We demonstrated that the dynamic posttranslational modification of proteins by O-linked β-N-acetylglucosamine (O-GlcNAcylation) is a key metabolic regulator of glucose metabolism. O-GlcNAcylation was induced at serine 529 of phosphofructokinase 1 (PFK1) in response to hypoxia. Glycosylation inhibited PFK1 activity and redirected glucose flux through the pentose phosphate pathway, thereby conferring a selective growth advantage on cancer cells. Blocking glycosylation of PFK1 at serine 529 reduced cancer cell proliferation in vitro and impaired tumor formation in vivo. These studies reveal a previously uncharacterized mechanism for the regulation of metabolic pathways in cancer and a possible target for therapeutic intervention.

Rapid physiological response is critical for the growth of tumors, which must satisfy the metabolic demands of increased cell proliferation in the face of a dynamically changing microenvironment. Cancer cells reprogram their cellular metabolism to generate molecules such as adenosine triphosphate (ATP), nucleotides, lipids, and reduced nicotinamide adenine dinucleotide phosphate (NADPH) to facilitate macromolecular synthesis and maintain redox homeostasis (1, 2). Although mutations in tumor suppressors and oncogenic pathways contribute to these altered metabolic phenotypes (1–3), such changes are slower and relatively static. In contrast, posttranslational modifications such as protein phosphorylation allow cells to respond rapidly and reversibly to a wide range of signals.

The dynamic posttranslational glycosylation of proteins with O-linked β-N-acetylglucosamine...
O-GlcNAcylation serves as a nutrient sensor to couple metabolic status to the regulation of signaling pathways (4–7). O-GlcNAc transferase (OGT) catalyzes the transfer of N-acetylglucosamine from uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) to serine or threonine residues of many intracellular proteins, including signaling proteins important for insulin resistance (5), oncogenes and tumor suppressors (6), and transcriptional coactivators that control gluconeogenesis (7). O-GlcNAc levels are increased in multiple tumor types, and OGT silencing inhibits breast tumor growth and prostate cancer metastasis (6, 8–9).

O-GlcNAcylation can be rapidly induced (10) and is dynamically sensitive to changes in cellular UDP-GlcNAc concentrations (4). UDP-GlcNAc is biosynthesized from several key metabolites, including glucose, glutamine, acetyl-coenzyme A, uridine, and ATP (11, 12). Consequently, UDP-GlcNAc may serve as a functional reporter of the status of various metabolic pathways. Indeed, UDP-GlcNAc and the hexosamine biosynthesis pathway couple growth factor–induced glutamine uptake to glucose metabolism through N-glycosylation of the interleukin-3 (IL-3) receptor (11). However, the fates of UDP-GlcNAc, particularly the functional consequences of dynamic O-GlcNAcylation in the regulation of cell metabolism, remain unknown.

To test whether O-GlcNAcylation directly couples nutrient sensing to cellular metabolism, we modulated O-GlcNAc concentrations and measured the effects on aerobic glycolysis. Global abundance of O-GlcNAc was increased by two- to fourfold in human lung cancer H1299 cells by overexpressing OGT or after pharmacological inhibition of β-N-acetylglucosaminidase (O-GlcNAcase or OGA), the glycosidase that removes O-GlcNAc, with O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc; Fig. 1A). Increasing the abundance...
of O-GlcNAc resulted in decreased rates of glucose metabolism relative to those of untreated cells under both normoxic and hypoxic conditions, as measured by the conversion of 5-3H-glucose to 3H2O, which is catalyzed by enolase in the penultimate step of glycolysis (Fig. 1B and fig. S1). Enhancing O-GlcNAcylation also led to reduced lactate production and lowered cellular concentrations of ATP (Fig. 1B). Similar effects were observed in other cells, including invasive human lung cancer A549 cells and human embryonic kidney 293T cells (fig. S2). Because glycolytic flux is 5 to 15 times higher in cancer cells than flux through other central pathways in cancer cells (13), small alterations in glycolysis can result in substantial changes in the relative flow of branching pathways (14).

To assess whether OGT-dependent glycosylation of protein substrates contributes to these effects, we stably depleted H1299 and 293T cells of OGT through the expression of short hairpin RNA (shRNA) (fig. S3). The inhibition of OGA in these OGT-deficient cells had no significant effect on glucose metabolism, lactate production, or ATP production (fig. S3).

Nearly all of the enzymes in the glycolytic pathway are putative substrates for OGT (15).

Fig. 2. Inhibition of PFK1 activity and oligomerization by glycosylation. (A) Relative activities of WT and S529A PFK1 (L isoform) purified from transfected 293T cells under normoxic or hypoxic conditions. Activities were measured in the presence of 100 μM F-2,6-BP and 3 mM ATP and were normalized with respect to the activity of WT PFK1 under normoxic conditions (n = 3 assays). (B) Oligomerization state of Flag-tagged PFK1 (L isoform) purified from 293T cells under normoxic or hypoxic conditions and from 293T cells overexpressing OGT or treated with PUGNAc under normoxic conditions. Complexes were resolved by nonreducing SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by Coomassie blue staining. (C) Coimmunoprecipitation (IP) of endogenous PFK1 with Flag-tagged WT or S529A PFK1 (L isoform) after OGT overexpression. Complexes were immunoprecipitated with a Flag antibody conjugated to agarose beads and analyzed by reducing SDS-PAGE, followed by immunoblotting with a PFK1 antibody. Error bars denote SEM. Statistical analysis was performed by Student’s t test (*P < 0.05).

Fig. 3. PFK1 glycosylation at Ser529 regulates glycolysis, increases PPP flux, and protects cells from ROS-mediated cell death. (A) Immunoblotting of H1299 cells stably expressing shRNA and rescue constructs. Flag-PFK1 levels were comparable to endogenous PFK1 levels. (B) Glycolytic rate and lactate production of H1299 cells rescued with WT or S529A PFK1 in the absence (Cont) or presence of OGT overexpression (n = 4 experiments). (C) PPP activity in WT or S529A PFK1 rescue cells in the absence (Cont) or presence of OGT overexpression, as measured by the rate of 14CO2 production from glucose via the PPP (n = 3 assays). (D) Percentage of central carbon flux from glucose to lactate flowing through the PPP in WT or S529A PFK1 rescue cells in the absence (Cont) or presence of OGT overexpression, as measured by reverse-phase triple-quadrupole liquid chromatography mass spectrometry. (E) NADPH and GSH levels in WT or S529A PFK1 rescue cells in the absence (Cont) or presence of OGT overexpression. NADPH and GSH concentrations are shown relative to WT PFK1 Cont and were assessed using a colorimetric assay and the thiol probe monochlorobimane, respectively (n = 4 experiments). (F) NADPH and GSH levels in WT or S529A PFK1 rescue cells under hypoxic conditions (n = 3 experiments). (G) Cellular ROS levels induced by varying concentrations of diamide in untreated H1299 cells (Cont) and H1299 cells overexpressing OGT, as measured by a fluorimetric assay. (H) Percentage of cell death induced by varying concentrations of hydrogen peroxide in untreated (Cont) and OGT-overexpressing H1299 cells, as measured by lactate dehydrogenase levels (n = 4 assays). Error bars denote SEM. Statistical analysis was performed by Student’s t test (*P < 0.05) for all figures.
Thus, we modulated amounts of O-GlcNAc in 293T cells and assayed the activity of each enzyme in the pathway. Increased amounts of O-GlcNAc led to decreased activity of phosphofructokinase 1 (PFK1), a major regulatory enzyme that controls flux through glycolysis (Fig. 1C). No change in the expression of PFK1 protein was observed (fig. S3). Enhancing the abundance of O-GlcNAc had little effect on other key regulatory points in the pathway, including hexokinase, phosphoglycerate kinase, and pyruvate kinase (fig. S4), nor did it affect other glycolytic enzymes.

To assess whether PFK1 is directly O-GlcNAcylated, we selectively labeled O-GlcNAc-modified proteins from 293T cell lysates with a non-native azido sugar through exposure to an exogenous galactosyltransferase enzyme that specifically glycosylates terminal GlcNAc sugars (15, 17) (fig. S5). Labeled proteins were then biotinylated through [3+2] azide-alkyne cycloaddition chemistry and isolated with streptavidinagarose beads. Immunoblotting of the purified proteins with an antibody to PFK1 showed a strong O-GlcNAcylation of PFK1 (Fig. 1D), which was further enhanced by overexpression of OGT (fig. S5). We also generated a stable cell line expressing Flag-tagged PFK1 and selectively labeled O-GlcNAc-modified proteins in the lysate with a 5-kD polyethylene glycol (PEG) mass tag to shift their molecular mass (18). Immunoblotting with an antibody to Flag enabled direct visualization of both the nonglycosylated and glycosylated species of Flag-PFK1 (Fig. 1E). The population of glycosylated PFK1 significantly increased upon OGT overexpression or OGA inhibition. Moreover, PFK1 glycosylation was induced under hypoxic conditions within minutes and accumulated in a time-dependent manner on 32.3 ± 3.8% of PFK1 (Fig. 1F and fig. S6). Glycosylation was also stimulated when cells were deprived of glucose (13.3 ± 2.2%, fig. S6), consistent with previous reports that O-GlcNAc levels and OGT expression are increased by nutrient deprivation and other forms of cell stress (19, 20).

PFK1 was glycosylated in multiple cell lines from human solid tumors, including breast, prostate, liver, colon, and cervical cells, and glycosylation was greater in malignant than in non-tumorigenic breast and prostate cell lines (fig. S7). Glycosylation of PFK1 also occurred in human breast and lung tumor tissues and was significantly elevated by two- to fourfold in the majority of tumors relative to tumor-adjacent normal tissues from the same patient (Fig. 1G and fig. S8). Low-stage (stages I and II) lung adenocarcinoma tumors exhibited on average a 1.8-fold increase in PFK1 glycosylation as compared to that of the matched normal tissue, whereas high-stage (stages III and IV) lung adenocarcinomas showed an average 3.2-fold increase in glycosylation. PFK1 glycosylation was not induced in rapidly proliferating normal mouse T lymphocytes and human dermal fibroblast cells, as compared to their quiescent counterparts (fig. S9). Thus, PFK1 is modified with O-GlcNAc in cancer cells both in vitro and in vivo, and glycosylation is increased specifically under conditions associated with tumorigenesis and tumor growth.

To identify the glycosylation site(s) on PFK1, we transiently overexpressed Flag-tagged PFK1 and OGT in 293T cells. After immunoprecipitation and proteolytic digestion of PFK1, O-GlcNAcylated peptides were enriched by wheat germ agglutinin lectin affinity chromatography and subjected to electron transfer dissociation mass spectrometry analysis. We identified a single site of glycosylation at Ser529, a highly conserved residue important for allosteric regulation of PFK1 by fructose-2,6-bisphosphate (F-2,6-BP) (21) (fig. S10). F-2,6-BP is the dominant activator of PFK1 at the high ATP concentrations (2 to 5 mM) found in cancer cells (22). The mutation of Ser529 to alanine (SS29A) abolished the glycosylation of PFK1 in 293T cells, whereas alanine mutation of Thr527 had no effect (fig. S10).

Although no structure of human PFK1 is available, we used the Saccharomyces cerevisiae structure, which shares 82% sequence identity within the F-2,6-BP binding site, and the rabbit structure, which shares 97% sequence identity, to generate structural models of rabbit PFK1 complexed to F-2,6-BP and O-GlcNAcylated rabbit PFK1 (fig. S11; the root mean square deviation between the rabbit and yeast structures was only 1.70 Å). Ser529 formed a hydrogen bond with the 2-phosphate group of F-2,6-BP, and the O-GlcNAc moiety occupied the F-2,6-BP-binding pocket, indicating that O-GlcNAcylation might inhibit PFK1 activity by blocking binding of F-2,6-BP and disrupting PFK1 oligomerization.

To further examine the effects of O-GlcNAcylation on PFK1 activity, we expressed human Flag-tagged PFK1 (L, M, and P isoforms) in 293T cells in the presence or absence of hypoxic conditions, which enhance PFK1 glycosylation. Increasing O-GlcNAcylation of PFK1 by 25 to 33% because of hypoxia decreased the activity of all three isoforms by 21 to 36%, with the L and P isoforms being most sensitive to glycosylation (Fig. 2A and fig. S12). We then focused on the L isoform of PFK1, whose expression is enhanced in multiple cancer cells (23). Hypoxia produced no significant change in PFK1 activity

![Fig. 4.](https://www.sciencemag.org)
when Ser\textsuperscript{529} was mutated to alanine (Fig. 2A). Similar effects on PFK1 activity were observed when O-GlcNAcylation was increased by means of other cellular treatments (fig. S13). Furthermore, glycosylation inhibited PFK1 activity across a wide ATP concentration range in the presence and absence of F-2,6-BP (fig. S14). Consistent with the importance of Ser\textsuperscript{529} in recognition of the allosteric activator, the activity of SS29A PFK1 was impaired at lower F-2,6-BP concentrations (fig. S15). Therefore, we examined the effects of glycosylation in the presence of endogenous F-2,6-BP concentrations in 293T cells or 8.5 μM F-2,6-BP, which is within the physiological range for cancer cells (24). In both cases, the activity of wild-type (WT) PFK1 was significantly lower than that of SS29A PFK1 when glycosylation was induced by hypoxia (fig. S16). Glycosylation thus exerts a strong inhibitory effect on PFK1 activity, and the mutation of Ser\textsuperscript{529} to Ala rescues the inhibitory effect. These results indicate that O-GlcNAcylation of PFK1 at Ser\textsuperscript{529} provides a mechanism to overcome the allosteric regulation of PFK1 by ATP and F-2,6-BP.

F-2,6-BP slows the dissociation of complexes of PFK1 and promotes the association of PFK1 into tetramers and higher oligomers with enhanced catalytic activity (16). We expressed Flag-tagged PFK1 in 293T cells under normoxic or hypoxic conditions. After hypoxia treatment, a fraction of PFK1 exhibited faster mobility during native gel electrophoresis (Fig. 2B). A similar shift in mobility was observed when PFK1 glycosylation levels were increased by OGT overexpression or OGA inhibition and when PFK1 was heat-denatured (fig. S17), suggesting that this complex represents a lower oligomeric state of PFK1. We also examined the association of Flag-tagged PFK1 with endogenous PFK1 by coimmunoprecipitation. Overexpression of OGT impaired the coimmunoprecipitation of PFK1 subunits, and this effect was blocked by alanine mutation of Ser\textsuperscript{529} (Fig. 2C). Thus, O-GlcNAcylation not only inhibits the activity of PFK1 but also appears to perturb the equilibrium between different oligomeric forms.

To test the effects of PFK1 glycosylation on cellular metabolism, we depleted endogenous PFK1 and stably expressed Flag-tagged WT or SS29A PFK1 in H1299 cells (henceforth referred to as WT PFK1 or SS29A PFK1 rescue cells; Fig. 3A). Upon OGT overexpression, cells expressing WT PFK1 exhibited reduced glycolysis and lactate production relative to control cells (Fig. 3B). No change in glycolytic rate or lactate production was observed in cells expressing SS29A PFK1 upon OGT overexpression.

Suppressing glycolysis can redirect metabolic flux down the oxidative pentose phosphate pathway (PPP) (25, 26), providing cells with pentose sugars for nucleotide and nucleic acid biosynthesis, as well as NADPH to combat oxidative stress (25–27). We observed both increased total and proportional flux through the oxidative PPP pathway, as measured by the amount of released \textsuperscript{14}CO\textsubscript{2} from [\textsuperscript{1-14}C]-glucose, and by relative accumulation of singly versus doubly \textsuperscript{13}C-labeled lactate from a [\textsuperscript{1,2-13}C]-glucose feed, when O-GlcNAcylation was enhanced in WT PFK1 rescue cells (Fig. 3, C and D). In contrast, PPP flux remained unaffected in SS29A PFK1 rescue cells; however, it was increased as compared to that of untreated WT PFK1 rescue cells, possibly because of inhibitory effects of the SS29A mutation on PFK1 activity (fig. S15).

PPP flux generates NADPH, which maintains a pool of reduced glutathione (GSH) and combats reactive oxygen species (ROS)–mediated cell death (24, 28). Consistent with increased PPP flux, enhancement of O-GlcNAC by OGT overexpression in WT PFK1 rescue cells led to 1.6-fold and 4-fold increases in amounts of NADPH and GSH, respectively (Fig. 3E). Blocking glycosylation of PFK1 at Ser\textsuperscript{529} prevented the increase in NADPH and partially prevented the increase in GSH. Amounts of NADPH and GSH were also increased under hypoxic conditions in WT PFK1 rescue cells as compared to those in SS29A PFK1 rescue cells (Fig. 3F). Furthermore, untargeted metabolic profiling by high-resolution flow-injection mass spectrometry (29) revealed enhanced steady-state concentrations of GSH, amino acids, and nucleotide precursors in WT PFK1 rescue cells relative to those in SS29A PFK1 rescue cells (table S1). We measured the sensitivity of H1299 cells to ROS-mediated cell death upon overexpression of OGT. Enhancing O-GlcNAcylation prevented the increase in ROS levels induced by diamide (Fig. 3G) and protected the cells from hydrogen peroxide–mediated cell death (Fig. 3H). Thus, increases in PPP flux induced by PFK1 glycosylation might help promote cancer cell survival.

Cells expressing the SS29A mutant proliferated more slowly than cells expressing WT PFK1 under hypoxic conditions, which is consistent with reduced flux through the PPP (Fig. 4A). The proliferation rate of WT PFK1-expressing cells was enhanced further upon OGT overexpression, whereas that of SS29A PFK1-expressing cells was unchanged. OGT overexpression increased, whereas OGT depletion decreased, cell proliferation under hypoxic conditions (Fig. 4B). Depletion of PFK1 abolished these effects, indicating that O-GlcNAcylation stimulates cell proliferation through a PFK1-dependent mechanism (although decreasing PFK1 expression may blunt the differences in cell growth).

We injected immunocompromised mice (nu/nu) with WT PFK1 or SS29A PFK1 rescue cells in the presence or absence of OGT overexpression (fig. S18) and assayed for tumor formation. Mice injected with SS29A PFK1 rescue cells showed increased tumor mass as compared to mice injected with WT PFK1 rescue cells (Fig. 4C). Moreover, overexpression of OGT in WT PFK1 rescue cells enhanced tumor growth but had no significant effect on SS29A PFK1 rescue cells. Protein immunoblot analysis confirmed that the Flag-tagged WT or SS29A PFK1 proteins were retained in the tumors and that WT PFK1 was O-GlcNAcylated (Fig. 4C). Under these conditions, glycosylation of PFK1 at Ser\textsuperscript{529} provides a critical growth advantage to tumor cells in vivo.

We demonstrated that O-GlcNAc glycosylation directly regulates glycolysis and reroutes metabolic flux through pathways critical for cancer cell proliferation and survival. O-GlcNAc can simultaneously sense and redirect flow through essential metabolic pathways, specifically through the modulation of PFK1 activity, adding a previously unrecognized mode of regulation to this glycolytic enzyme. Furthermore, because UDP-GlcNAc represents a key point of pathway integration and enables the cell to monitor the balance between glucose and glutamine uptake (11, 12), O-GlcNAcylation of PFK1 may provide an important mechanism to link the availability of both carbon and nitrogen sources for the cell to the production of metabolites necessary for sustaining rapid tumor growth.

Hypoxia also activates PFK1 glycosylation, thereby redirecting a larger fraction of the glucose flux through the PPP and increasing biosynthetic precursors, as well as reducing power from increased NADPH and GSH, to impart a growth advantage to cancer cells. Our results suggest that dynamic physiological inhibition of PFK1 may be a major regulatory point for central carbon flow. Blocking PFK1 glycosylation to enhance its activity and reset cellular metabolism toward normal cell growth could therefore provide a new strategy to combat cancer.
Neurexin and Neuroligin Mediate Retrograde Synaptic Inhibition in *C. elegans*

Zhita Hu,1,2 Sabrina Hom,1,2,3 Tambudzai Kudze,3 Xia-Jing Tong,1,2 Seungwon Choi,1,2,3 Gayane Aramuni,4 Weiqi Zhang,5 Joshua M. Kaplan1,2,3

The synaptic adhesion molecules neurexin and neuroligin alter the development and function of synapses and are linked to autism in humans. Here, we found that *Caenorhabditis elegans* neurexin (NRX-1) and neuroligin (NLG-1) mediated a retrograde synaptic signal that inhibited neurotransmitter release at neuromuscular junctions. Retrograde signaling was induced in mutants lacking a muscle microRNA (miR-1) and was blocked in mutants lacking NLG-1 or NRX-1. Release was rapid and abbreviated when the retrograde signal was on, whereas release was slow and prolonged when retrograde signaling was blocked. The retrograde signal adjusted release kinetics by inhibiting exocytosis of synaptic vesicles (SVs) that are distal to the site of calcium entry. Inhibition of release was mediated by increased presynaptic levels of tomosyn, an inhibitor of SV fusion.

Neurexin (NRX-1) and neuroligin (NLG-1) are membrane proteins that mediate trans-synaptic adhesion in *Caenorhabditis elegans* and mice. The two proteins are linked to autism in humans. In this study, the authors investigated whether these proteins mediate a retrograde signal that inhibits neurotransmitter release at the neuromuscular junctions (NMJs) in *C. elegans*. They found that neurexin and neuroligin mediate a retrograde synaptic signal that inhibits neurotransmitter release at neuromuscular junctions. This signal is induced in mutants lacking a muscle microRNA (miR-1) and is blocked in mutants lacking NLG-1 or NRX-1.

The retrograde signal was shown to be rapid and abbreviated when the signal was on, and slow and prolonged when the signal was blocked. This signal was found to adjust release kinetics by inhibiting exocytosis of synaptic vesicles (SVs) that are distal to the site of calcium entry. Inhibition of release was mediated by increased presynaptic levels of tomosyn, an inhibitor of SV fusion.

**Supplementary Materials**

www.sciencemag.org/cgi/content/full/337/6097/975/DC1

Materials and Methods

Figs. S1 to S18

Table S1

References (30–44)

PDB Coordinates of Lowest-Energy Glycosylated PFK1 Structure

22 March 2012; accepted 29 June 2012

10.1126/science.1222278